Life Sciences

Gotham Therapeutics Launches with $54 Million Co-Led by Versant Ventures, Forbion and SR One

Edward Kim | |

Pioneering RNA modification to control gene expression (Image: Gotham Therapeutics)

Equillium's $70 Million IPO Expected This Week for Immuno-Inflammatory Diseases

Edward Kim | |

Lead candidate targeting graft-versus-host disease (GvHD) (Image: Equillium).

Novartis to Get Expedited FDA Review of Secondary Progressive Multiple Sclerosis Drug

Edward Kim | |

Phase 3 data shows siponimod has beneficial effects on disability, relapses and MRI disease activities (Image: Novartis)

Osmotica Pharmaceuticals' $125 Million IPO Expected Next Week

Edward Kim | |

$246 million in revenue in 2017 from specialty neurology, women's health and generics. Phase 3 in MS and droopy eyelid (Image: Osmotica Pharmaceuticals).

Zealand Pharma Enrolls First Patient in Phase 3 Trial for Short Bowel Syndrome

Edward Kim | |

Glepaglutide was shown in Phase 2 trial to increase intestinal absorption after only 3 weeks of treatment (Image: Zealand Pharma)

Epizyme Raises $75 Million in Follow-on Offering to Advance Epigenetic Cancer Therapies

Edward Kim | |

Lead candidate, tazemetostat, in Phase 2 for non-Hodgkin lymphoma, solid tumors and mesothelioma (Image: Epizyme).

Paratek Gets FDA Approval for Moderate to Severe Acne Treatment

Edward Kim | |

FDA is due to decide later this week on Paratek's lead compound for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia (Image: Paratek)

Insmed Gets FDA Approval for First Mycobacterium Avium Complex (MAC) Lung Disease Therapy

Edward Kim | |

First drug granted approval under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (Image: Bronchiectasis News Today)

KSQ Therapeutics Raises $80 Million Series C for Cancer Therapies

Edward Kim | |

Proprietary CRISPRomics discovery engine has yielded 12 oncology programs in just 12 months (Image: KSQ Therapeutics)

Geron Announces Termination of Janssen Collaboration in Blood Cancer

Edward Kim | |

Geron regains global rights to the imetelstat program and will focus on initiating Phase 3 studies (Image: Geron)


Symbol Last Price Change % Change






INTERVIEW: CEO Dr. Martin Eaton - Heads Up Checkup Host & Contributor Silvia Davi interviewing CEO of Heads Up Checkup, Dr. Martin Eaton.